3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Leukemia
23
Prostatic Neoplasms
12
Lymphoma
11
Burkitt Lymphoma
9
Lymphoma, Large B-Cell, Diffuse
4
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large-Cell, Immunoblastic
3
Leukemia, Myeloid, Acute
3
Leukemia, Biphenotypic, Acute
3
Dendritic Cell Sarcoma, Interdigitating
3
Anemia, Refractory, with Excess of Blasts
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Leukemia, Myelomonocytic, Chronic
2
Hodgkin Disease
2
Anemia, Refractory
2
Stomatitis
1
Rhabdoid Tumor
1
Pituitary Neoplasms
1
Pituitary Diseases
1
Pancreatic Neoplasms
1
Oral Ulcer
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Myeloproliferative Disorders
1
Interventions
dexpanthenol
1
Triamcinolone Acetonide
1
Tetracycline
1
Provitamins
1
Prednisone
1
Panitumumab
1
Minocycline
1
Irinotecan
1
IFL protocol
1
Hydrocortisone
1
Gels
1
Erlotinib Hydrochloride
1
Doxycycline
1
Dapsone
1
Clindamycin
1
Anti-Bacterial Agents
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Exanthema
×
Hydrocortisone
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts